AVR
Anteris Technologies Global Corp.
NASDAQ · Healthcare · Medical - Devices · AU
$6.18
+2.15%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$6.09
From 52W high−41.53%
Volume1.36M
Market cap$602.29M
P/E (TTM)—
P/S (TTM)268.6x
Div yield—
Key dataOct 19, 2026
Open
$6.09
From 52W high
−41.53%
Volume
1.36M
Market cap
$602.29M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−3.5x
P/E (TTM)
—
RSI (14)
27.6
MomentumView details →
1D Return
+2.15%
YTD Return
+23.95%
SummaryUpdated Jun 1, 2026
Anteris Technologies Global Corp. (NASDAQ:AVR) is an Australian-based structural heart company that develops medical devices for treating aortic stenosis, a condition where the heart's aortic valve becomes narrowed and restricts blood flow. Founded in 1999 and headquartered in Toowong, Australia, the company went public on the NASDAQ in December 2024. Anteris focuses on creating innovative solutions for patients with heart valve disease, particularly through its transcatheter aortic valve replacement technology and proprietary anti-calcification tissue treatment.
Similar companies
Latest newsMore news →
Anteris Aus Operations Pty Ltd amended its Supply & Quality Agreement with Harvey Industries Group Pty Ltd, extending the term until the earlier of December 31, 2026 or the effective date of a replacement agreement.26d agoAnteris Technologies Global Corp. granted equity awards to Vice Chairman and CEO Wayne Paterson, David St Denis, and Matthew McDonnell effective September 12, 2026.32d ago